Immune Therapeutics, Inc. Announces Exclusive Agreement for Sale of Lodonal in Kenya Valued at Over $31 Million Sep 6, 2017 09:12AM
Immunovative, Inc. (IMUN) Reports Exclusive Agreement for Sale Of Lodonal in Kenya Valued At Over $31 Million Sep 6, 2017 08:14AM
Immune Therapeutics, Inc. Announces Exclusive Agreement For Sale Of Lodonal In Kenya Valued At Over $31 Million Sep 6, 2017 08:05AM
Immune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc. Aug 23, 2017 09:04AM
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’I May 31, 2017 09:15AM


May 22, 2017 09:25AM CORRECTING and REPLACING: Immune Therapeutics, Inc.
May 22, 2017 08:42AM Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria
Apr 25, 2017 11:37AM Immune Therapeutics, Inc. Files Lodonal New Drug Application in Kenya